Prevention of contamination by biopsy needle track contamination using a novel adriamycin-loaded gelatin sponge by Zhen-Feng Li et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Li et al. World Journal of Surgical Oncology 2013, 11:169
http://www.wjso.com/content/11/1/169RESEARCH Open AccessPrevention of contamination by biopsy needle
track contamination using a novel adriamycin-
loaded gelatin sponge
Zhen-Feng Li, Jian-Min Li*, Jun Yan, Zhi-Ping Yang, Xin Li and Qiang YangAbstract
Background: The gold standard of tumor diagnosis is histological examination of a biopsy; however, there is
concern that tumor cell dissemination along the needle track during percutaneous biopsy can cause local tumor
relapse. We aimed to evaluate the value of an adriamycin (ADM)-loaded gelatin sponge in preventing tumor cell
contamination along the biopsy needle track.
Methods: Data were obtained from 40 patients who were diagnosed by core needle biopsy as having
osteosarcoma and who were followed up at our hospital between 2008 and 2011. Of the 40 patients, 20 had the
needle biopsy tracks filled with ADM-loaded absorbable gelatin sponge immediately after the biopsy specimen was
obtained, while the other 20 did not. All 40 patients underwent limb-salvage surgery, and specimens were obtained
from the biopsy track for histopathologic examination of multiple sections.
Results: On histological examination, there was less tumor cell contamination along the biopsy tracks in the ADM
group.
Conclusion: Use of ADM-loaded absorbable gelatin sponge may prevent tumor cell contamination of a biopsy
track, and reduce the possibility of consequent tumor relapse.
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The gold standard of tumor diagnosis is histological
examination of a biopsy. Core needle biopsy is becoming
the main method of obtaining a sample for pathologic
examination for diagnosis of osteosarcoma; however,
there is concern that tumor cell dissemination along the
needle track during percutaneous might cause local
tumor relapse. A few recent reports indicated that
tumor cell contamination [1] and local metastasis [2-4]
did occur along the needle puncture track. To decrease
the likelihood of tumor cell contamination along the
track during core needle biopsy, we designed a novel
adriamycin (ADM) loaded gelatin sponge and use this to
embolize the biopsy needle track. Specimens from the
biopsy track were later obtained, and the pathologic re-
sults were evaluated and compared with the specimens* Correspondence: gkljm@163.com
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reproduction in any medium, provided the orof biopsy track. The histological examination showed
that there was less tumor cell contamination along the
biopsy tracks in the ADM-treated group.Methods
During the period 2008 to 2011, 40 patients with
suspected osteosarcoma underwent core needle biopsy.
Before biopsy, the 40 patients were randomly divided
using a digital table into the ADM (experimental) and
non-ADM (control) groups, with equal numbers of pa-
tients in each. Details of the clinical data of both groups
are illustrated in Table 1.
We used a homemade spring-loaded cutting needle to
perform the biopsy (Figure 1). This unique spiral-blade
needle was in the shape of a spiral screw, with which
tumor tissue could be obtained. The biopsy method was
as follows. After local anesthesia was administered, the
skin over the biopsy site was punctured with the biopsy
needle. The inner needle was then withdrawn from thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical data of the groups
Characteristic ADM group Non-ADM group



















Figure 1 The puncture needle: the inner needle, outer
cylindrical cuff and spring-loaded cutting needle.
Figure 2 Gelatin sponge with 1 mg adriamycin (ADM). The ADM
is visible as a red color on the sponge.
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cutting needle through the outer cylindrical cuff. Once
the surface of the tumor was reached, the cutting needle
was slowly rotated forward into the tumor mass in a
clockwise direction, resulting in the screw groove of the
spring-loaded cutting needle being filled with tumor tis-
sue. The spiral blade was then withdrawn, and the bi-
opsy tissue was removed from the needle. By repeating
these steps, tumor samples at different depths and sites
could be collected. The tumor samples were then sent
for pathologic examination.
After a satisfactory tumor sample was obtained with
the spiral needle, the experimental (ADM) group was
treated with ADM. A gelatin sponge containing 1 mg
ADM (prepared from a bottle containing 10 mg ADM,
diluted with 1 ml normal saline, and 0.1 ml used) was
inserted into the track through the working tunnel, until
it reached the surface of the tumor mass (Figure 2). A
second piece of gelatin sponge then inserted through the
outer cylindrical cuff to a point about 0.5 cm above the
tumor mass capsule; this sponge did not contain ADM,
in order to prevent the spread of the drug to healthy
tissue.
For the control group, no gelatin sponge was used to
fill the biopsy track, the biopsy syringe was withdrawn
immediately after the biopsy was taken, and the biopsy
site was compressed with a dressing.The histopathology confirmed that all 40 biopsy speci-
mens were osteosarcoma, and all 40 patients had limb-
salvage operations. During the surgery, the needle tracks
were resected en bloc with the tumor mass, and the
biopsy-track specimens were separated from the tumor
mass for pathologic examination. The measured dis-
tances between the skin puncture and tumor was about
2.5 cm (range 1.5 to 3.2 cm), and the needle track
Figure 3 Magnetic resonance imaging scan of osteosarcoma in
the control.
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formalin and cut sections into tissue blocks with the 2
mm spacing paralleling the needle within 1 cm distance
to the puncture track, and the tissue blocks were
cut sections 6 μm thick. All specimens from both
groups were evaluated histologically by an experienced
pathologist.
Results
All biopsy procedures were successfully performed. No
acute complications, such as skin necrosis, infection, or
damage to blood vessels or nerves were noted after bi-
opsy. The punctured needle holes healed uneventfully in
all cases.
The tumor cell necrosis rates of tumor mass speci-
mens in the ADM and non-ADM groups were 8/20 and
9/20, respectively for higher grades (Huvos III/IV >90%),
and 12/20 and 11/20 for lower grades (Huvos I/II <
90%). Of the 40 patients, 37 (2 of ADM group and 1 of
non-ADM group could not be contacted) had follow-up
data available, and the average follow-up time was 29
months (range 5 to 42). Endpoints included the recur-
rence, metastasis, death and the most recent follow-up.
The rates of recurrence outside the biopsy site were
5.6% (1/18) for the ADM group and 11% (2/19) for the
non-ADM group; the 3-years event-free survival rates
(EFS: recurrence, metastasis and death) were 61% (11/
18) and 63.1% (12/19), respectively, and the overall
survival (OS) rates were 66.7% (12/18) and 73.7% (14/19,
respectively). There was no significant difference
(P < 0.05) between the ADM and non-ADM groups.
Outcome details are illustrated in Table 2.
No tumor seeding was found along the needle tracks
based on the pathologic results for the ADM group. In
the control group, tumor cells were found along the nee-
dle tracks in three cases (Figures 3, 4 and 5). Using the
small sample t-test a significant difference (P < 0.05) was
found between the ADM and non-ADM groups.
Discussion
Pathologic examination is the most important proced-
ure for diagnosis of bone tumors compared withTable 2 Patient outcome after treatment
Characteristic ADM group Non-ADM group
Tumor cell necrosis
Huvos III, IV 40% (8/20) 45% (9/20)
Huvos I, II 60% (12/20) 55% (11/20)
3-year EFS 61% (11/18) 63.1% (12/19)
3-year OS 66.7% (12/18) 73.7% (14/19)
Non-biopsy site recurrence 5.6% (1/18) 10.5% (2/19)
Tumor cells 0/20 3/20
EFS, event-free survival; OS, overall survival.radiography, computed tomography, and magnetic
resonance imaging. Biopsy methods include pre-
operative open biopsy, core needle biopsy and the
intra-operative biopsy. However, both the open and the
intra-operative biopsy carry the risks of non-healing of
incision and tumor implantation of needle track.
Enneking [5] reported that the local contamination
rate by tumor cells of intra-operative incision was 39%.
With the development of diagnostic technology, the
core needle biopsy is being used extensively because of
its simple manipulation, minimal invasiveness into the
adjacent tissue and reliable results [6].Figure 4 The needle track specimen.
Figure 5 Fat and tumor cells in the pathology examination.
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semination of tumor cells along needle tracks. After in-
vestigating cases of local metastasis after limb-salvage
surgery, one group reported that the incidence of tumor
cell contamination along the biopsy needle track was
about 6.6% [1] Other reports showed that local tumor
cell contamination occurred after needle biopsy without
biopsy-track treatment [2-4]. Schwartz [7] reported that
local tumor metastasis occurred in 89% of tracks after
needle biopsy of sarcoma, and there were 57 cases of
metastasis along the biopsy needle track from 1950 to
1997. Consequently, it is important to find ways to re-
duce the incidence of local tumor cell contamination
along biopsy needle tracks. Wiksell [8] reported that no
tumor cells were found in fine needle tracks after treat-
ment with radiofrequency pulses to the tracks. However,
the diameters of most core needles used for bone tu-
mors are large, exceeding 16G [6,9]. To prevent local
tumor cell contamination along such needle tracks, we
used ADM-loaded gelatin sponge to embolize the needle
tracks after biopsy, and evaluated the outcome with
pathologic examination.
During the biopsy, we obtained the tumor specimen
using a spring-loaded cutting needle, within the outer
cylindrical cuff. In this way, there was minimal invasive-
ness to the surrounding tissue, and sufficient tumor
specimens could be obtained from different depths and
in different directions through the same working tunnel.
Furthermore, the location of the puncture point guided
the position of the future surgical incision so that the
needle track could be resected en bloc with the tumor
mass during the final operation [10].
The appropriate length of follow-up is an important
area of controversy [11]. The reporte recurrence rates
after osteosarcoma treatment range from 2.6 to 7.9%
[12,13], and the mean time to local recurrence has been
variously reported as 13, 14, 18 and 27 months[12,14-17]. In this study, our mean follow-up for recur-
rence was 29 months. Because the study was mainly
concerned with recurrence along the biopsy track, and
the tracks were resected in the surgery, thus we consider
that 29 months was sufficient to detect any recurrence.
However, we will continue to follow up these patients.
Another controversial point is identifying whether a
tumor is a recurrence or the result of tumor cell seeding
[11]. In our study, we resected all biopsy tracks during
the surgery. However, one recurrence site occurred near
the incision, thus we could not be sure whether it was in
fact a recurrence or was the result of tumor cell seeding.
We found tumor cells in the biopsy-track specimens
in three patients in the non-ADM group, thus the rate
of tumor cell contamination was 15% (3/20) which is
similar to results from a previous report [1]. There was
no significant difference in EFS and OS between the two
groups. Saghieh [18] reported that limb-salvage opera-
tions could be performed safely using standard ap-
proaches without the need for biopsy-track excision, as
the incidence of tumor cell seeding was believed to be
low; however, that study included only 10 cases. Most
other reports have recommended resecting the biopsy
track to decrease the incidence of possible tumor relapse
from the needle track.
ADM is a chemotherapy drug used routinely in the
treatment of osteosarcoma. Its pharmacological mechan-
ism is probably related to combining the cell DNA, then
inhibiting nucleic acid synthesis and mitosis. ADM is
usually administered by intravenous injection. Its cyto-
toxicity is proven and it is a strong vesicant leakage of
ADM outside the superficial veins can lead to local tis-
sue inflammation, swelling, skin ulcers, necrosis, and
even dysfunction of limb; however, there has been no re-
port of adverse events occurring with mild ADM leakage
outside the deep veins. The cases in our study all had
deep bone tumors. Above the surface of the tumor mass,
there is skin, subcutaneous fat, deep fascia and muscle,
which all have the effect of minimizing the local tissue
damage from ADM. In our study, the ADM-loaded gel-
atin sponge was placed just above the surface of the
tumor mass through the needle track, and the superficial
part of the track was filled with a plain gelatin sponge
without ADM to prevent the spread of the drug. The re-
sults of our study showed that the small dose of ADM
deep located on the surface of tumor mass was able to
provide a local chemotherapeutic effect without causing
serious damage to the surrounding normal tissues.
Conclusion
We consider that the use of ADM-loaded gelatin sponge
during biopsy could provide a useful method for embol-
ism in needle tracks. The ADM-loaded gelatin sponge
prevented blood (possibly containing tumor cells)
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cell contamination is more likely to happen in malignant
tumors with a rich blood supply), providing both an
embolization function and a local chemotherapeutic ef-
fect. This method is simple, safe, and effective, and it
may be particularly useful after biopsy of bone tumors
with favorable soft-tissue coverage.
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